Regardless of the processes that underlie the different CSF ratios of ASC to CD14+ myeloid cells, the ratio in our cohort distinguishes between MS and non-MS ADS including MOGAD and could be further investigated for its potential to provide an MS disease-specific CSF signature at time of initial CSF evaluation. The gene discussed is CD14; the disease is myeloid sarcoma.